聚乙二醇干扰素α治疗慢性乙型肝炎疗效的预测指标相关研究进展OA

Pegylated interferon alpha(Peg-IFN-α)demonstrates dual antiviral and immunomodulatory properties,which allow a subset of chronic hepatitis B(CHB)patients to attain high hepatitis B surface antigen(HBsAg)clearance rates within a limited treatment period.This,in turn,presents the potential for clinical cure and a reduced risk of hepatocellular carcinoma.Nevertheless,its clinical application is restricted by high costs,significant adverse effects,and considerable inter-individual variability in therapeutic response.This highlights the need for accurate patient stratification.This review systematically assesses host-related factors(including age,gender,baseline alanine aminotransferase levels,interferon-related gene polymorphisms,and hepatic fibrosis status)and virological parameters(such as HBV genotype,viral mutations,viral load,and antigen/novel viral marker levels)that impact Peg-IFN-α treatment outcomes.By clarifying their predictive value and mechanistic roles,analyzing current therapeutic challenges,and suggesting individualized treatment strategies,this work aims to promote the optimization of clinical management protocols for CHB.